SBFMW

FORT LAUDERDALE, FL / ACCESS Newswire / October 22, 2026 / (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced a one…

0 million upfront with an additional $14.4 million of potential aggregate gross proceeds upon the exercise of warrantsFORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2026 / (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and…

The financing will provide additional working capital for Sunshine Biopharma, but the inclusion of two warrants per unit creates potential future share dilution for existing shareholders.

FORT LAUDERDALE, FL / ACCESS Newswire / October 8, 2026 / (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced the…

Sunshine Biopharma, Inc. (SBFM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

* Launch introduces ondansetron 4 mg and 8 mg tablets for nausea and vomiting associated with chemotherapy, radiation therapy and surgery * Global ondansetron market projected to reach $2. Ondansetron is the generic equivalent of the brand name, Zofran®.

The Company had previously published laboratory results on its library of Anti-Coronavirus compounds in August 2024 (J. 2024, 67, 13681−13702) and more recently in March 2026 (J.

Sunshine Biopharma Inc. (NASDAQ:SBFM) on Wednesday announced it advanced its lead Coronavirus drug candidate into IND-enabling studies.

FORT LAUDERDALE, FL / ACCESS Newswire / August 31, 2026 / (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its Atenolol tablets of 25mg, 50mg and 100mg for the Canadian market.

Sunshine Biopharma Inc. (NASDAQ:SBFM) on Wednesday released an update regarding its proprietary oncology initiative, outlining key next steps for its K1.1 mRNA lipid nanoparticle program.

Global anti-hypertensive drug market projected to reach $37.24 billion by 2034 Enalapril is a widely prescribed ACE inhibitor used to treat hypertension, heart failure and left ventricular dysfunction Sunshine Biopharma expects Enalapril tablets in ...

Sunshine Biopharma Inc. (NASDAQ:SBFM) announced on Wednesday that it has secured regulatory approval to introduce its generic Enalapril tablets across the Canadian market, signaling a significant strategic step into first-line antihypertensive treatments.